Horizon Investments LLC Has $468,000 Stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Horizon Investments LLC raised its holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 3.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 5,983 shares of the company’s stock after buying an additional 221 shares during the quarter. Horizon Investments LLC’s holdings in GE HealthCare Technologies were worth $468,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Darwin Wealth Management LLC acquired a new stake in GE HealthCare Technologies in the 3rd quarter valued at approximately $31,000. Continuum Advisory LLC grew its holdings in GE HealthCare Technologies by 101.8% in the 3rd quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock valued at $31,000 after buying an additional 168 shares during the last quarter. Bank of Jackson Hole Trust acquired a new stake in GE HealthCare Technologies in the 4th quarter valued at approximately $32,000. Flagship Wealth Advisors LLC acquired a new stake in GE HealthCare Technologies in the 4th quarter valued at approximately $34,000. Finally, OFI Invest Asset Management acquired a new stake in GE HealthCare Technologies in the 4th quarter valued at approximately $34,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

GE HealthCare Technologies Price Performance

GE HealthCare Technologies stock opened at $81.81 on Friday. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 0.83. The company has a market capitalization of $37.41 billion, a PE ratio of 18.89, a price-to-earnings-growth ratio of 3.19 and a beta of 1.13. GE HealthCare Technologies Inc. has a one year low of $74.51 and a one year high of $94.80. The business has a 50 day simple moving average of $87.08 and a 200 day simple moving average of $86.05.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its earnings results on Thursday, February 13th. The company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.26 by $0.19. The business had revenue of $5.32 billion during the quarter, compared to the consensus estimate of $5.33 billion. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. On average, sell-side analysts forecast that GE HealthCare Technologies Inc. will post 4.68 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

GEHC has been the topic of a number of research analyst reports. Jefferies Financial Group raised GE HealthCare Technologies from a “hold” rating to a “buy” rating and raised their target price for the company from $95.00 to $103.00 in a report on Wednesday, January 8th. Citigroup raised their price objective on GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Wells Fargo & Company raised their price objective on GE HealthCare Technologies from $96.00 to $103.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. Finally, The Goldman Sachs Group upgraded GE HealthCare Technologies from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $85.00 to $100.00 in a research report on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.75.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.